Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Cash from Financing Activities: 2009-2025

Historic Cash from Financing Activities for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Sep 2025 value amounting to -$956.0 million.

  • UNITED THERAPEUTICS's Cash from Financing Activities fell 1391.42% to -$956.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year decrease of 3.94%. This contributed to the annual value of -$1.3 billion for FY2024, which is 10444.54% down from last year.
  • As of Q3 2025, UNITED THERAPEUTICS's Cash from Financing Activities stood at -$956.0 million, which was down 381.37% from -$198.6 million recorded in Q2 2025.
  • UNITED THERAPEUTICS's Cash from Financing Activities' 5-year high stood at $55.5 million during Q4 2022, with a 5-year trough of -$1.1 billion in Q1 2024.
  • Moreover, its 3-year median value for Cash from Financing Activities was -$74.7 million (2024), whereas its average is -$228.6 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first surged by 640.00% in 2022, then plummeted by 2,297.53% in 2024.
  • Over the past 5 years, UNITED THERAPEUTICS's Cash from Financing Activities (Quarterly) stood at $7.5 million in 2021, then skyrocketed by 640.00% to $55.5 million in 2022, then plummeted by 267.21% to -$92.8 million in 2023, then rose by 19.50% to -$74.7 million in 2024, then tumbled by 1,391.42% to -$956.0 million in 2025.
  • Its Cash from Financing Activities stands at -$956.0 million for Q3 2025, versus -$198.6 million for Q2 2025 and -$93.8 million for Q1 2025.